Amniox Medical Appoints CEO

Atlanta, Ga.-based Amniox Medical Inc., a provider of amniotic membrane-based products for wound care and reconstructive surgery, has named Thomas J. Dugan as CEO. Dugan previously joined the firm’s Board of Directors in 2014.

Prior to his arrival at Amniox, Dugan was president and a board member of SurgiQuest Inc. From 2008 until 2013, he served as president, North America, of Smith & Nephew Wound Management and served on the global executive management team of Smith & Nephew’s $1.3 billion wound management business.

Previously, Dugan served as the senior vice president of sales and marketing for SonoSite Inc., a developer of hand-carried ultrasound. Dugan also served as president of InterVascular Inc. and corporate vice president of business development of Datascope.
He was the vice president of marketing and ran business development for U.S. Surgical/Tyco Healthcare (now Covidien) during a period of significant merger and acquisition activity. Earlier in his career, Dugan held various sales, marketing and international positions with C.R. Bard, Puritan-Bennett and Johnson & Johnson. He also served on the board of directors of RITA Medical Systems Inc. and two other venture-backed medical device companies. Dugan also was previously chair of the Wound Healing and Tissue Regeneration Sector of the Advanced Medical Technology Association (usually called AdvaMed) and was on the board of the Medical Imaging Trade Association.

“We are very pleased to have Tom join Amniox as chief executive officer,” said Amy Tseng, founder and CEO of TissueTech Inc., the Miami, Fla.-based parent company of Amniox. “Tom brings a wealth of experience in the medical device industry and an impressive track record in the wound care market.”

Founded in 2011 to serve the orthopedic and wound care markets, Amniox develops regenerative therapies processed from amniotic membrane and umbilical cord matrix using its proprietary Cryotek technology. The company procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety.

TissueTech, the parent company of both Amniox Medical and BioTissue Inc., makes regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets.

“I am joining Amniox at a pivotal and exciting moment for the organization,” said Dugan. “We have had tremendous growth in both the wound care and surgical markets, and I am confident my partnership with Aaron and his team will be characterized by success.
Additionally, with our industry leadership position as the only provider of a human tissue matrix composed of both umbilical cord and amniotic membrane, we can continue to accelerate the growth of the company.